Page last updated: 2024-08-24

triazoles and doravirine

triazoles has been researched along with doravirine in 91 studies

Research

Studies (91)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	35 (38.46)	24.3611
2020's	56 (61.54)	2.80

Authors

Authors	Studies
Asante-Appiah, E; Burch, J; Campeau, LC; Cauchon, E; Côté, B; DiStefano, D; Ducharme, Y; Falgueyret, JP; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Li, Y; Lu, M; Miller, MD; Sachs, N; Tawa, P; Witmer, M; Yan, Y	1
Asante-Appiah, E; Bayly, C; Bédard, L; Blouin, M; Burch, JD; Campeau, LC; Cauchon, E; Chan, M; Chefson, A; Côté, B; Coulombe, N; Cromlish, W; Debnath, S; Deschênes, D; Ducharme, Y; Dupont-Gaudet, K; Falgueyret, JP; Forget, R; Gagné, S; Gauvreau, D; Girardin, M; Guiral, S; Langlois, E; Li, CS; Nguyen, N; Ouellet, S; Papp, R; Plamondon, S; Roy, A; Roy, S; Seliniotakis, R; St-Onge, M; Tawa, P; Truchon, JF; Vacca, J; Wrona, M; Yan, Y	1
Feng, M; Grobler, JA; Hazuda, DJ; Lai, MT; Miller, MD; Wang, D	1
Ancona, JK; Anderson, MS; Butterton, JR; Cilissen, C; De Lepeleire, I; Dockendorf, MF; Gilmartin, J; Guo, Y; Liu, R; Tetteh, E; Van Bortel, L; Wagner, JA	1
Cao, Y; Gauthier, DR; Humphrey, G; Itoh, T; Journet, M; Mangion, I; Sherry, BD; Tschaen, DM	1
Anderson, MS; Butterton, JR; De Lepeleire, I; Gilmartin, J; Guo, Y; Liu, R; Robberechts, M; Schürmann, D; Sobotha, C; Wagner, F; Wagner, JA; Yee, KL	1
Blair, W; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Miller, MD; Sachs, NA; Xu, M	1
Akram, A; Ambrose, Z; Hughes, SH; Melody, K; Pauly, GT; Schneider, JP; Smith, SJ	1
Cao, Y; Gauthier, DR; Helmy, R; Sheng, H; Yang, R; Zhang, LK; Zheng, J	1
Anderson, MS; Butterton, JR; Fan, L; Hussaini, A; Khalilieh, S; Liu, R; Rizk, ML; Ross, LL; Shah, V; Song, I; Yee, KL	1
Auger, P; Di Spirito, M; Fan, L; Iwamoto, M; Khalilieh, SG; Lai, MT; Liu, R; Sanchez, RI; Triantafyllou, I; Yee, KL	1
Fan, L; Iwamoto, M; Jordan, H; Khalilieh, S; Maklad, N; Martell, M; Sanchez, RI; Triantafyllou, I; Yee, KL	1
Auger, P; Fan, L; Iwamoto, M; Khalilieh, S; Lasseter, KC; Liu, R; Marbury, T; Sanchez, RI; Stypinski, D; Triantafyllou, I; Yee, KL	1
Behm, MO; Fackler, P; Fan, L; Yee, KL	1
Behm, MO; Fackler, P; Levine, V; Liu, R; Panebianco, D; Yee, KL	1
Anderson, MS; Brejda, J; Butterton, JR; Judge, T; Khalilieh, SG; Liu, R; Manthos, H; Sanchez, RI; Yee, KL	1
Dunzo, E; Fan, L; Heber, W; Hussaini, A; Iwamoto, M; Khalilieh, SG; Liu, R; Triantafyllou, I; Yee, KL	1
Anderson, MS; Behm, MO; Butterton, JR; Fan, L; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Li, Y; Liang, Y; Liu, R; Lu, B; Sanchez, RI; Tatavarti, A; Yee, KL	1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X	1
Colombier, MA; Molina, JM	1
Eissa, NA; Wilby, KJ	1
Álvarez, H; Llibre, JM; Yzusqui, M	1
Deeks, ED	1
Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Di Carlo, D; Gennari, W; Marcelin, AG; Paraskevis, D; Perno, CF; Santoro, MM; Soulie, C; Sterrantino, G; Storto, A; Zazzi, M	1
Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J	1
Claussen, A; de Greef, R; Ouerdani, A; Wenning, L; Yee, KL	1
Bleasby, K; Chan, GH; Fillgrove, KL; Houle, R; Lin, M; Lu, B; Newton, DJ; Palamanda, J; Sanchez, RI	1
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M	1
Ankrom, W; Fan, L; Iwamoto, M; Khalilieh, S; Mitra, P; Sanchez, RI; Sterling, LM; Stoch, SA; Triantafyllou, I; Wolford, D; Yee, KL	1
Anderson, MS; Fan, L; Iwamoto, M; Khalilieh, SG; Laethem, T; Rasmussen, S; Sanchez, RI; Sura, M; van Bortel, L; van Lancker, G; Yee, KL	1
Deschamps, K; Fan, L; Iwamoto, M; Jordan, HR; Khalilieh, SG; Martell, M; Sanchez, RI; Vaynshteyn, K; Yee, KL	1
Cislak, D; Fan, L; Iwamoto, M; Jordan, HR; Khalilieh, S; Martell, M; Sanchez, RI; Yee, KL	1
Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y	1
Bouhajib, M; Fan, L; Iwamoto, M; Khalilieh, S; Sanchez, RI; Searle, S; Vaynshteyn, K; Yee, KL	1
Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X	1
DeJesus, E; Hanna, G; Hwang, C; Kumar, S; Lombaard, J; Martin, E; Molina, JM; Orkin, C; Rodgers, A	1
Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X	1
Boyle, A; Khoo, S; Marzolini, C; Moss, CE	1
Blevins, SR; Chastain, DB; Cluck, DB; Hester, EK	1
Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A	1
Hazuda, D; Hwang, C; Lai, MT	1
Grobler, JA; Markowitz, M	1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K	1
Dormer, PG; Forrest, WP; Helmy, R; Reibarkh, M; Rudd, ND; Walsh, PL; Williamson, RT; Wuelfing, WP	1
Abdi, B; Andreoni, M; Antinori, A; Armenia, D; Bertoli, A; Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Forbici, F; Gennari, W; Jary, A; Marcelin, AG; Mussini, C; Perno, CF; Santoro, MM; Soulie, C; Storto, A	1
Aguilera, A; Alejos, B; Álvarez, M; Blanco, JR; Caballero, E; Espinosa, N; García, F; García-Álvarez, M; García-Bujalance, S; García-Fraile, LJ; Gómez-Sirvent, JL; Guerrero-Beltrán, C; Iborra, A; Imaz, A; Iribarren, JA; Martínez, M; Martínez-Sanz, J; Masiá, M; Montero, M; Moreno, S; Olalla, J; Peraire, J; Portilla, J; Rivero, M; Rodríguez, C; Vidal-Ampurdanes, MC	1
DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL	1
Boffito, M; Connolly, S; Fedele, S; McClure, M; Milinkovic, A; Moyle, G; Pereira, B; Thomas, L; Wang, X; Yener, D	1
Alves Saldanha, S; André, P; Buclin, T; Cavassini, M; Choong, E; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Günthard, HF; Marzolini, C	1
Talwani, R; Temesgen, Z	1
Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R	1
Azeem, SM; Frey, KM; Muwonge, AN; Tabassum, T	1
Dockendorf, MF; Fackler, PH; Fan, L; Iwamoto, M; Khalilieh, SG; Mittal, S; Stoch, SA; Triantafyllou, I; Yee, KL	1
Fulco, PP; Herity, LB	1
Hewlett, K; Hughes, SH; Pauly, GT; Schneider, JP; Smith, SJ	1
Iwamoto, M; Khalilieh, S; Sanchez, R; Stoch, SA; Wenning, L; Yee, KL	1
Kandala, B; Vaddady, P; Yee, KL	1
Arribas, JR; Battegay, M; Béguelin, C; Bhagani, S; Cinque, P; Collins, S; Cotter, A; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, P; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Winston, A	1
Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P	1
Boccuto, A; Dragoni, F; Giammarino, F; Giannini, A; Hosseini, BA; Saladini, F; Shafer, RW; Vicenti, I; Zazzi, M	1
Cabalu, TD; Dreyer, D; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Kuo, Y; Liu, Y; McClain, S; Sanchez, RI; Stoch, SA; Triantafyllou, I; Wenning, L; Yee, KL	1
Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ	1
Abdel-Daim, MM; Afify, MA; Ahmed, IGG; Alkahtani, TA; Alrowili, ASM; Altulayhi, RI; Bin-Jumah, M; Ghozy, S	1
Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H	1
Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K	1
Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A	1
Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ	1
Alegete, P; Kancherla, P; Kokkirala, TK; Suryakala, D	1
Brenner, BG; Ibanescu, RI; Oliveira, M; Routy, JP; Thomas, R	1
Hans, L; Moorhouse, M; Steegen, K; Venter, WD; Wensing, AM	1
Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; DeJesus, E; Eves, K; Grandhi, A; Hanna, GJ; Hwang, C; Molina, JM; Olsen Klopfer, S; Robertson, MN; Sklar, P; Yazdanpanah, Y	1
Godela, R; Gummadi, S	1
Bouchet-Crivat, F; Lê, MP; Mandelbrot, L; Pencolé, L; Peytavin, G	1
Ciccullo, A; D'Angelillo, A; Di Giambenedetto, S; Farinacci, D; Iannone, V; Lombardi, F; Tamburrini, E; Visconti, E	1
Challenger, E; Else, L; Imaz, A; Khoo, S; Niubó, J; Penchala, SD; Podzamczer, D; Prieto, P; Rigo-Bonin, R; Saumoy, M; Scévola, S; Silva-Klug, A; Soriano, I; Tiraboschi, J	1
Asante-Appiah, E; Grobler, JA; Hazuda, D; Lai, J; Martin, EA; Petropoulos, CJ; Sklar, P; Walworth, C; Wan, H; Yang, D	1
Aherfi, S; Banti, E; Dhiver, C; Motte, A; Solas, C	1
Khoo, S; Stockdale, AJ	1
Antinori, S; Baldelli, S; Bisinella, GC; Cattaneo, D; Cossu, MV; Fusi, M; Gervasoni, C; Meraviglia, P; Micheli, V; Resnati, C; Vimercati, S	1
Cattelan, AM; Leoni, D; Mazzitelli, M; Putaggio, C; Sasset, L	1
Cai, W; Chen, M; Lan, G; Lan, Y; Liang, S; Ma, Y; Ni, M; Sun, Z; Wang, J; Yan, L; Yu, F; Zhang, F; Zhang, H; Zhang, X	1
Bailón, L; Curran, A; Else, L; Graterol, F; Imaz, A; Khoo, S; Moltó, J; Paredes, R; Pérez, F; Ramos, N; Sandoval, D	1
Ciccullo, A; D'Angelillo, A; Farinacci, D; Giambenedetto, SD; Iannone, V; Lamanna, F; Lombardi, F; Moschese, D; Passerotto, RA	1
Bociąga-Jasik, M; Hlebowicz, M; Jakubowski, P; Parczewski, M; Raczyńska, A; Scheibe, K; Szetela, B; Szymczak, A; Urbańska, A; Łojewski, W	1
Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A	1
Bukkems, VE; Burger, DM; Colbers, A; Freriksen, JJM; Greupink, R; Roelofsen, D; Svensson, EM; van Drongelen, J; van Ewijk-Beneken Kolmer, EWJ; van Hove, H	1
Baker, CR; Fulco, PP; Porter, AM	1
Arnold, E; Bijnens, M; Das, K; De Wijngaert, B; Herdewijn, P; Martinez, SE; Nguyen, H; Pannecouque, C; Schols, D; Singh, AK; Uyttersprot, K	1
Antoni, MD; Castelli, F; Cattelan, AM; Fabbiani, M; Ferraresi, A; Lapadula, G; Mazzitelli, M; Putaggio, C; Quiros-Roldan, E; Ripamonti, D; Zuglian, G	1
Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y	1
Cottrell, ML; Imaz, A; Kashuba, AD; Podzamczer, D; Schauer, AP; Sykes, C	1

Reviews

13 review(s) available for triazoles and doravirine

Article	Year
Doravirine: a review. Current opinion in HIV and AIDS, 2018, Volume: 13, Issue:4 Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles	2018
Clinical Pharmacokinetics and Drug Interactions of Doravirine. European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:6 Topics: Drug Interactions; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2018
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review AIDS reviews, 2018, Volume: 20, Issue:3 Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load	2018
Doravirine: First Global Approval. Drugs, 2018, Volume: 78, Issue:15 Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles	2018
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3 Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2019
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clinical pharmacokinetics, 2019, Volume: 58, Issue:12 Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2019
Doravirine: A Return of the NNRTI Class? The Annals of pharmacotherapy, 2020, Volume: 54, Issue:1 Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles	2020
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Current opinion in HIV and AIDS, 2020, Volume: 15, Issue:1 Topics: Animals; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viral Load	2020
Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:2 Topics: Anti-HIV Agents; Cytochrome P-450 CYP3A; HIV Infections; HIV-1; Humans; Japan; Pyridones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Triazoles	2020
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. Clinical drug investigation, 2020, Volume: 40, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Drug Interactions; Female; Food-Drug Interactions; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2020
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. Journal of acquired immune deficiency syndromes (1999), 2020, 12-15, Volume: 85, Issue:5 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles	2020
Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis. Environmental science and pollution research international, 2021, Volume: 28, Issue:9 Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyridones; Triazoles	2021
Doravirine: its role in HIV treatment. Current opinion in HIV and AIDS, 2022, 01-01, Volume: 17, Issue:1 Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2022

Trials

30 trial(s) available for triazoles and doravirine

Article	Year
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antiviral therapy, 2015, Volume: 20, Issue:4 Topics: Adult; Area Under Curve; Chromatography, Liquid; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Administration Schedule; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Triazoles	2015
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS (London, England), 2016, Jan-02, Volume: 30, Issue:1 Topics: Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Male; Middle Aged; Placebos; Plasma; Pyridones; RNA, Viral; Treatment Outcome; Triazoles; Young Adult	2016
A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical pharmacokinetics, 2017, Volume: 56, Issue:6 Topics: Adult; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Fasting; Female; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2017
Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:2 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; Headache; Healthy Volunteers; Humans; Male; Middle Aged; Pyridones; Triazoles	2017
Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:2 Topics: Adult; Area Under Curve; Atorvastatin; Drug Interactions; Female; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2017
Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. Journal of clinical pharmacology, 2017, Volume: 57, Issue:6 Topics: Adult; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2017
Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects. Antiviral therapy, 2017, Volume: 22, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Area Under Curve; Biological Availability; Drug Administration Schedule; Fasting; Female; Healthy Volunteers; Humans; Male; Middle Aged; Patient Safety; Pyridones; Reverse Transcriptase Inhibitors; Sex Factors; Triazoles	2017
The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Clinical drug investigation, 2017, Volume: 37, Issue:6 Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles	2017
A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. Clinical drug investigation, 2017, Volume: 37, Issue:10 Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2017
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:4 Topics: Absorption, Physiological; Administration, Intravenous; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Humans; Male; Metabolome; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tissue Distribution; Triazoles; Young Adult	2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. The lancet. HIV, 2018, Volume: 5, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load	2018
A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents. Journal of clinical pharmacology, 2019, Volume: 59, Issue:8 Topics: Adult; Aluminum Hydroxide; Antacids; Drug Interactions; Female; Humans; Magnesium Hydroxide; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Simethicone; Triazoles	2019
Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers. Clinical pharmacology in drug development, 2020, Volume: 9, Issue:1 Topics: Adult; Area Under Curve; Drug Interactions; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2020
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. Journal of acquired immune deficiency syndromes (1999), 2019, 08-01, Volume: 81, Issue:4 Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult	2019
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone. Clinical pharmacology in drug development, 2020, Volume: 9, Issue:2 Topics: Adult; Analgesics, Opioid; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Outcome Assessment, Health Care; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2020
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 03-17, Volume: 70, Issue:7 Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles	2020
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 03-17, Volume: 70, Issue:7 Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Treatment Outcome; Triazoles	2020
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antiviral therapy, 2019, Volume: 24, Issue:6 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Triazoles; Viral Load; Young Adult	2019
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. Journal of acquired immune deficiency syndromes (1999), 2019, 12-01, Volume: 82, Issue:4 Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles	2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. The lancet. HIV, 2020, Volume: 7, Issue:1 Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult	2020
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate. AAPS PharmSciTech, 2020, Feb-13, Volume: 21, Issue:3 Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult	2020
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clinical and translational science, 2020, Volume: 13, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prospective Studies; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Tuberculosis; Young Adult	2020
Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:5 Topics: Administration, Oral; Adult; Delayed-Action Preparations; Dried Blood Spot Testing; Female; Half-Life; Humans; Injections, Intramuscular; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2020
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin. Journal of clinical pharmacology, 2021, Volume: 61, Issue:3 Topics: Adult; Alkynes; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Pyridones; Reverse Transcriptase Inhibitors; Rifabutin; Rifampin; Triazoles; Young Adult	2021
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 07-01, Volume: 73, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles	2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS (London, England), 2021, 04-01, Volume: 35, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles	2021
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss	2021
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. The lancet. HIV, 2021, Volume: 8, Issue:6 Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Triazoles; Young Adult	2021
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. The Journal of antimicrobial chemotherapy, 2022, 06-29, Volume: 77, Issue:7 Topics: Chromatography, Liquid; Dialysis Solutions; HIV Infections; Humans; Kidney Failure, Chronic; Male; Pyridones; Renal Dialysis; Tandem Mass Spectrometry; Triazoles	2022
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine. Journal of acquired immune deficiency syndromes (1999), 2022, 09-01, Volume: 91, Issue:1 Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles	2022

Other Studies

48 other study(ies) available for triazoles and doravirine

Article	Year
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:3 Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Macrophages; Monocytes; Pyridones; Triazoles; Virus Replication	2014
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorganic & medicinal chemistry letters, 2014, Feb-01, Volume: 24, Issue:3 Topics: Animals; Anti-HIV Agents; Cells, Cultured; Crystallography, X-Ray; Dogs; Drug Discovery; Drug Resistance, Viral; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Pyridones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Triazoles	2014
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Selection, Genetic; Triazoles	2015
Highly efficient synthesis of HIV NNRTI doravirine. Organic letters, 2015, Mar-20, Volume: 17, Issue:6 Topics: Aldehydes; HIV Infections; HIV Reverse Transcriptase; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2015
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Viral; Gene Expression; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Pyridones; Rilpivirine; Triazoles	2016
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. Journal of acquired immune deficiency syndromes (1999), 2016, 08-15, Volume: 72, Issue:5 Topics: Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles; Virus Replication	2016
Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis. Journal of mass spectrometry : JMS, 2016, Volume: 51, Issue:10 Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Contamination; HIV Infections; Humans; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles	2016
The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects. Clinical drug investigation, 2017, Volume: 37, Issue:7 Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Half-Life; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Rifampin; Triazoles; Young Adult	2017
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. The Journal of antimicrobial chemotherapy, 2019, 03-01, Volume: 74, Issue:3 Topics: Anti-HIV Agents; Drug Resistance, Viral; France; Gene Frequency; Greece; HIV Infections; HIV-1; Humans; Italy; Mutation, Missense; Prevalence; Pyridones; Triazoles	2019
Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4 Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Triazoles; Young Adult	2019
Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4 Topics: Animals; Biological Transport; Cell Line; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; HEK293 Cells; Hepatocytes; Humans; Kinetics; Madin Darby Canine Kidney Cells; Membrane Transport Proteins; Pyridones; Triazoles	2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. International journal of antimicrobial agents, 2019, Volume: 53, Issue:4 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles	2019
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5 Topics: Adult; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Fluorenes; Humans; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Pyridones; Quinoxalines; Sulfonamides; Triazoles	2019
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5 Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult	2019
Rational Design of Doravirine: From Bench to Patients. ACS infectious diseases, 2020, 01-10, Volume: 6, Issue:1 Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Design; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Translational Research, Biomedical; Triazoles	2020
Probing in Vitro Release Kinetics of Long-Acting Injectable Nanosuspensions via Flow-NMR Spectroscopy. Molecular pharmaceutics, 2020, 02-03, Volume: 17, Issue:2 Topics: Chemistry, Pharmaceutical; Drug Compounding; Drug Liberation; Drug Stability; Excipients; In Vitro Techniques; Injections; Magnetic Resonance Spectroscopy; Nanoparticles; Particle Size; Pyridones; Solubility; Suspensions; Triazoles	2020
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. The Journal of antimicrobial chemotherapy, 2020, 04-01, Volume: 75, Issue:4 Topics: Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2020
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. The Journal of antimicrobial chemotherapy, 2020, 05-01, Volume: 75, Issue:5 Topics: Algorithms; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; Humans; Mutation; Prevalence; Pyridones; Spain; Triazoles	2020
Pharmacokinetics of once-daily doravirine over 72 h following drug cessation. The Journal of antimicrobial chemotherapy, 2020, 06-01, Volume: 75, Issue:6 Topics: Pharmaceutical Preparations; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2020
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI Journal of mass spectrometry : JMS, 2020, Volume: 55, Issue:6 Topics: Amides; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Limit of Detection; Linear Models; Piperazines; Pyridones; Reference Standards; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles	2020
Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors. Current HIV research, 2020, Volume: 18, Issue:4 Topics: Allosteric Site; Anti-HIV Agents; Binding Sites; Drug Resistance, Viral; Enzyme Assays; Gene Expression; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thermodynamics; Triazoles; Urea	2020
Doravirine Use in Treatment-Experienced HIV-Positive Patients. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:1 Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. Chemical biology & drug design, 2021, Volume: 97, Issue:1 Topics: Anti-HIV Agents; Binding Sites; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Pyridones; Pyrimidines; Rilpivirine; Triazoles	2021
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1. Antimicrobial agents and chemotherapy, 2020, 10-20, Volume: 64, Issue:11 Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles	2020
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV medicine, 2020, Volume: 21, Issue:10 Topics: Age Factors; Anti-Retroviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Triazoles	2020
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. The Journal of antimicrobial chemotherapy, 2021, 01-01, Volume: 76, Issue:1 Topics: Anti-HIV Agents; Clone Cells; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles	2021
Changes in weight and BMI with first-line doravirine-based therapy. AIDS (London, England), 2021, 01-01, Volume: 35, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load	2021
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis. The Journal of antimicrobial chemotherapy, 2021, 04-13, Volume: 76, Issue:5 Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles	2021
A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form. Biomedical chromatography : BMC, 2021, Volume: 35, Issue:8 Topics: Chromatography, High Pressure Liquid; Drug Stability; Lamivudine; Limit of Detection; Linear Models; Pyridones; Reproducibility of Results; Tablets; Tenofovir; Triazoles	2021
Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir. The Journal of antimicrobial chemotherapy, 2021, 07-15, Volume: 76, Issue:8 Topics: Anti-HIV Agents; Cell Culture Techniques; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. Journal of the International AIDS Society, 2021, Volume: 24, Issue:5 Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Pyridones; Retrospective Studies; South Africa; Triazoles	2021
A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets. Annales pharmaceutiques francaises, 2021, Volume: 79, Issue:6 Topics: Chromatography, High Pressure Liquid; Lamivudine; Pyridones; Tablets; Tenofovir; Triazoles	2021
Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model. The Journal of antimicrobial chemotherapy, 2021, 08-12, Volume: 76, Issue:9 Topics: Cotyledon; HIV-1; Humans; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Pyridones; Triazoles	2021
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV. Journal of acquired immune deficiency syndromes (1999), 2021, 09-01, Volume: 88, Issue:1 Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 05-30, Volume: 74, Issue:10 Topics: HIV Infections; HIV-1; Humans; Pyridones; Triazoles; Virus Replication	2022
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates. Antimicrobial agents and chemotherapy, 2021, 11-17, Volume: 65, Issue:12 Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
High penetration of doravirine in the central nervous system: What are the benefits? Infectious diseases now, 2022, Volume: 52, Issue:2 Topics: Central Nervous System; Humans; Pyridones; Triazoles	2022
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. AIDS (London, England), 2021, 12-01, Volume: 35, Issue:15 Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Tenofovir; Triazoles	2021
Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis. Medicine, 2021, Dec-30, Volume: 100, Issue:52 Topics: Aged; Aged, 80 and over; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Male; Middle Aged; Oxazines; Piperazines; Polypharmacy; Pyridones; Retrospective Studies; Treatment Outcome; Triazoles; Viral Load	2021
Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. The Journal of antimicrobial chemotherapy, 2022, 03-31, Volume: 77, Issue:4 Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2022
Evaluation of doravirine-based regimen population target in a large Italian clinical center. Antiviral therapy, 2021, Volume: 26, Issue:3-5 Topics: Anti-HIV Agents; HIV-1; Humans; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients. Antiviral therapy, 2021, Volume: 26, Issue:3-5 Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Poland; Prevalence; Pyridones; Reverse Transcriptase Inhibitors; Triazoles	2021
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report. International journal of STD & AIDS, 2022, Volume: 33, Issue:7 Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load	2022
Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments. Clinical pharmacokinetics, 2022, Volume: 61, Issue:8 Topics: Female; Humans; Maternal-Fetal Exchange; Models, Biological; Perfusion; Placenta; Pregnancy; Pyridones; Triazoles	2022
Administration of Crushed Doravirine via Nasojejunal Feeding Tube in a Patient With Treatment-Experienced Human Immunodeficiency Virus. Journal of pharmacy practice, 2023, Volume: 36, Issue:4 Topics: HIV; Humans; Intubation, Gastrointestinal; Pyridones; Triazoles	2023
Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine. Proceedings of the National Academy of Sciences of the United States of America, 2022, 07-26, Volume: 119, Issue:30 Topics: Anti-HIV Agents; Cryoelectron Microscopy; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutation; Nitriles; Protein Conformation; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles	2022
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Medicine, 2022, Jul-29, Volume: 101, Issue:30 Topics: Anti-HIV Agents; DNA-Directed RNA Polymerases; Female; HIV Infections; Humans; Integrase Inhibitors; Male; Middle Aged; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Triazoles	2022
Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma. Journal of pharmaceutical and biomedical analysis, 2022, Oct-25, Volume: 220 Topics: Amides; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Raltegravir Potassium; Reproducibility of Results; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Triazoles	2022